Loading…
Metagenomi Therapeutics, Inc. is projected to rise to $1.47 by 2027, a +9% move from its current price of $1.35. MGX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.32 | $1.35 | $1.38 | +0.03% |
| May 30 | $1.31 | $1.35 | $1.39 | +0.05% |
| May 31 | $1.30 | $1.35 | $1.40 | +0.08% |
| Jun 1 | $1.29 | $1.35 | $1.41 | +0.10% |
| Jun 2 | $1.29 | $1.35 | $1.42 | +0.13% |
| Jun 3 | $1.28 | $1.35 | $1.43 | +0.16% |
| Jun 4 | $1.28 | $1.35 | $1.43 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.28 | $1.35 | $1.43 | +0.18% |
| Week 2 | $1.25 | $1.35 | $1.47 | +0.37% |
| Week 3 | $1.23 | $1.36 | $1.50 | +0.55% |
| Week 4 | $1.21 | $1.36 | $1.52 | +0.73% |
| Week 5 | $1.20 | $1.36 | $1.55 | +0.92% |
| Week 6 | $1.19 | $1.36 | $1.57 | +1.10% |
| Week 7 | $1.18 | $1.37 | $1.59 | +1.29% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. Its lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia.
It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs.
The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Metagenomi Therapeutics, Inc. trades under the MGX ticker in the Healthcare sector. The current price is $1.35 and the company carries a market cap of $50.82M, with a rank of 4592.
The price outlook combines near-term neutral momentum with longer-term bullish potential. Forecasts show 2026 trending with a min of $1.25, an avg of $1.35, and a max of $1.70, followed by a sequence of annual avg values that rise toward higher levels later in the decade and into the 2030s. By 2030 the avg is $1.44 and the max is $2.03, with a 6.8% ROI.
From 2032 onward, forecasts turn bullish, with 2032–2050 presenting higher averages and expanding upside, including a 2032 avg of $1.85 rising to a 2050 avg of $4.28 and a 217.4% ROI in 2050.
A major floor 18.8% below — a decisive break under it would weaken the trend.
The nearest floor, 7.4% below — buyers have tended to step in here.
The nearest ceiling, 13.3% above — a clean break opens room to run.
A major ceiling 30.4% above — clearing it would confirm fresh momentum.
Key MGX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MGX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.33 | Buy | $1.34 | Buy |
| MA 10 | $1.32 | Buy | $1.34 | Buy |
| MA 20 | $1.36 | Sell | $1.36 | Sell |
| MA 50 | $1.39 | Sell | $1.41 | Sell |
| MA 100 | $1.49 | Sell | $1.51 | Sell |
| MA 200 | $1.79 | Sell | $1.74 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.48 | Neutral |
| Stoch RSI (14) | 91.76 | Sell |
| CCI (20) | -10.36 | Neutral |
| Williams %R (14) | -41.18 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -4.26 | Sell |
| Bollinger %B (20,2) | 0.47 | Neutral |
| Stochastic %K (14) | 58.82 | Neutral |
| TRIX (15) | -0.28 | Sell |
| Awesome (5,34) | -0.06 | Sell |
| Ultimate (7,14,28) | 52.42 | Neutral |
| Momentum (10) | 0.00 | Neutral |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 1.36 | Sell |
| ADX (14) | 12.83 | Neutral |
| ATR (14) | 0.03 | Info |
The short-term technical picture is bearish. RSI14 is 50, with the price trading below the SMA200 ($1.79) and near the SMA50 ($1.40).
Support is noted at $1.25, with resistance at $1.53. The 30-day range runs from $1.16 to $1.57, indicating a relatively tight swing around the current level.
Annualized volatility stands at 40%, underscoring notable near-term variability.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.25 | $1.35 | $1.69 | 0% | Neutral | |
| $1.19 | $1.47 | $1.91 | +9% | Neutral | |
| $1.10 | $1.39 | $1.86 | +3% | Neutral | |
| $1.10 | $1.41 | $1.93 | +5% | Neutral | |
| $1.11 | $1.45 | $2.02 | +7% | Neutral | |
| $1.16 | $1.54 | $2.18 | +14% | Neutral | |
| $1.37 | $1.84 | $2.66 | +36% | Bullish | |
| $1.39 | $1.88 | $2.76 | +39% | Bullish | |
| $1.35 | $1.85 | $2.74 | +37% | Bullish | |
| $1.41 | $1.96 | $2.94 | +45% | Bullish | |
| $1.85 | $2.70 | $4.27 | +100% | Bullish | |
| $2.70 | $4.27 | $7.28 | +216% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.25 | $1.35 | $1.59 | +0.00% |
| June 2026 | $1.20 | $1.40 | $1.67 | +3.50% |
| July 2026 | $1.17 | $1.38 | $1.67 | -1.06% |
| August 2026 | $1.16 | $1.37 | $1.67 | -0.71% |
| September 2026 | $1.17 | $1.39 | $1.71 | +1.57% |
| October 2026 | $1.16 | $1.38 | $1.70 | -0.81% |
| November 2026 | $1.13 | $1.35 | $1.67 | -2.64% |
| December 2026 | $1.13 | $1.36 | $1.69 | +0.74% |
Click any year to see its month-by-month MGX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect MGX to range from $1.25 to $1.69 through 2026. The $1.35 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The MGX price prediction for 2027 points to an average of $1.47 (low $1.19, high $1.91) — a potential gain of +9% on today's $1.35. Price action looks broadly range-bound.
In 2028, MGX is projected to trade between $1.10 and $1.86, averaging $1.39 — a potential gain of +3% from today's $1.35. That is -5% versus the projected 2027 average. A consolidation phase looks the most probable path here.
Metagenomi Therapeutics, Inc.'s 2029 outlook centres on $1.41, within a $1.10 to $1.93 range. That is up +2% on the projected 2028 average. That marks a +5% change versus current levels. Price action looks broadly range-bound.
By 2030, MGX could reach as high as $2.02, with a base case around $1.45 and support toward $1.11 — roughly +7% from $1.35. A consolidation phase looks the most probable path here.
Expect MGX to range from $1.16 to $2.18 through 2031. The $1.54 average target implies a +14% move from current prices. That is up +6% on the projected 2030 average. Price action looks broadly range-bound.
The MGX price prediction for 2032 points to an average of $1.84 (low $1.37, high $2.66) — a potential gain of +36% on today's $1.35. Buyers look set to stay in control over this stretch.
In 2033, MGX is projected to trade between $1.39 and $2.76, averaging $1.88 — a potential gain of +39% from today's $1.35. That is up +2% on the projected 2032 average. Momentum favours further upside here.
Metagenomi Therapeutics, Inc.'s 2034 outlook centres on $1.85, within a $1.35 to $2.74 range. That is -2% versus the projected 2033 average. That marks a +37% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, MGX could reach as high as $2.94, with a base case around $1.96 and support toward $1.41 — roughly +45% from $1.35. Momentum favours further upside here.
Expect MGX to range from $1.85 to $4.27 through 2040. The $2.70 average target implies a +100% move from current prices. That is up +38% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The MGX price prediction for 2050 points to an average of $4.27 (low $2.70, high $7.28) — a potential gain of +216% on today's $1.35. Momentum favours further upside here.
Investing $1,000 in MGX today (≈ 740.740741 MGX) could be worth
$3,163.18
+$2,163.18 (+216%) by 2050 · US Dollar
Based on the average projected MGX price of $4.27 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MGXwould be worth at today's price.
$1,000 invested in MGX on May 27, 2025 (≈ 602.409651 MGX) would be worth
$813.25
-$186.75 (-18.7%) today · 0.81× · US Dollar
Based on a MGX entry price of $1.66 vs. today's $1.35.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.29 | $1,046.51 | +4.7% |
| 1 month ago | $1.48 | $912.16 | -8.8% |
| 3 months ago | $1.6 | $843.75 | -15.6% |
| 6 months ago | $1.75 | $771.43 | -22.9% |
| 1 year ago | $1.66 | $813.25 | -18.7% |
| All time (2.3y) ago | $10.31 | $130.94 | -86.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MGX forecast.
Our base-case forecast reaches $2.70 around 2040.
Implied market cap at $2.70: $101.65M
In the multi-year view, the forecast shows a clear shift from neutral to bullish sentiment starting in 2032. The 2026–2031 period is labeled NEUTRAL, with 2026 avg $1.35, 2027 avg $1.47, 2028 avg $1.38, 2029 avg $1.41, 2030 avg $1.44, and 2031 avg $1.53. ROIs for these years range from 0% to 13.4%, reflecting modest upside.
From 2032 to 2035, sentiment becomes BULLISH, with 2032 avg $1.85 (ROI 37.2%), 2033 avg $1.88 (ROI 39.2%), 2034 avg $1.84 (ROI 36.5%), and 2035 avg $1.97 (ROI 45.7%). The mid-decade period shows continued upside momentum as averages rise into higher levels.
By 2040 the avg is $2.70 with ROI of 99.7%, and by 2050 the avg is $4.28 with ROI of 217.4%. These late-stage figures reflect the potential for meaningful upside, albeit as a forecast with inherent uncertainty. These are estimates, not guarantees.
Tap a question to reveal the answer.
2030 min $1.10, avg $1.44, max $2.03; ROI 6.8%; sentiment NEUTRAL.
Near term is NEUTRAL (e.g., 2026–2031), with higher upside implied from 2032 onward. 2032–2050 show bullish sentiment and higher avg prices, with ROIs reaching up to 217.4% by 2050.
Yes. In 2030 the max is $2.03, and later years show higher max values: 2032 max $2.70, 2033 max $2.78, 2034 max $2.77, and 2035 max $2.99.
$50.82M.
Metagenomi Therapeutics, Inc. Community Discussion
0Share your Metagenomi Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.